The Faber Report
- Wealth Funds May Invest if Europe Finds Debt Solution: China Fund Exec
- Economist Nouriel Roubini's Firm Is For Sale
- Outcome of Euro Zone Crisis Still Impossible to Predict
- Energy Sector Has Undergone 'Tectonic Change': CEO
- Netflix's Self-Inflicted Wound
- Why BofA Is Exiting HCA Stake
- Yahoo Hires UBS, Allen to Navigate Tough Times
- Bartz Ouster From Yahoo Comes with a Bad Quarter
- Euphoria Over Buffett's $5 Billion BofA Investment Subsides
- Has Hewlett-Packard Made Itself a Takeover Target?
FABER REPORT VIDEO
RSS FEED
COMMUNITY
RECENT POSTS: THE STRATEGY SESSION
Sanofi To Send 'Bear Hug' Letter Within 72 Hours
Text Size 
CNBC Anchor and Reporter
In the next 72 hours Sanofi-Aventis, the very large French pharmaceutical company, will send a "bear hug" letter [an offer to buy shares for a much higher per-share price than the company is worth] to Genzyme outlining its desire to buy the biotech company.
 |
Source: Genzyme |
The price at this point is anybody's guess, according to people familiar with the matter.
If Sanofi [SNY
Loading...
()
] moves ahead with an unsolicited offer for Genzyme [GENZ
Loading...
()
], there will be plenty of biotech investors and investment bankers shaking their heads in wonderment, particularly if it is at a price well above Genzyme’s current level.
That’s because of the manufacturing problems that have plagued Genzyme’s yields on its key drugs (Cerezyme and Fabryzyme) and because the FDA continues to closely monitor Genzyme’s progress in solving its issues.
Even if Sanofi were able to do significant due diligence, (which it won’t if it launches an unsolicited bid) sources who have dealt with manufacturing issues in the production of drugs tell me it is still very difficult to assess whether those issues have been fully resolved.
Genzyme has begun to lose market share to competitors given its limited supply of drugs. But there is also another potential danger from the lack of supply—that doctors will find a smaller dosage of the drugs as effective as the usual dose.
Even if Genzyme were to get its supply up sharply and regain market share, if doctors find their patients get the same benefit from a lower dosage, it could cost Genzyme revenues.
Of course, this is all supposition. But if you’re the new CEO of a giant French drug company considering doing a hostile acquisition that might force you to pay a big multiple of Genzyme’s peak earnings ($4.00 a share) you are certainly taking a bold, but risky step.
Related Links:
_____________________________
_____________________________
More from The Faber Report:
thefaberreport.cnbc.com and now on Twitter @DAVIDFABER_CNBC
Questions? Comments? Write to .
Data is a real-time snapshot *Data is delayed at least 15 minutes
